Last updated on February 2018

Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Schizophrenia/Schizoaffective Disorder


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Schizophrenia | Psychosis
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • 18 years of age or older;
  • Suffer from schizophrenia/schizoaffective disorder meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria;
  • Have a total baseline score on the Brief Psychiatric Rating Scale (BPRS) 45;
  • Be capable and willing to provide written informed consent to participate in this study;
  • Agree to abide by the study protocol and its restrictions and be able to complete all aspects of the study, including all visits and tests

Exclusion Criteria:

  • Patients posing a serious suicidal risk and/or violence as judged by the investigator;
  • Patients with a current Axis I diagnosis of:
  • Delirium
  • Dementia
  • Amnestic and other cognitive disorder;
  • Patients with a history of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic or euthyroid for 6 months;
  • Patients who meet DSM-IV-TR criteria for any significant current substance abuse;
  • Patients with:
  • hepatic insufficiency (three times the upper limit of normal (ULN) for aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)); liver transplant recipient; cirrhosis of the liver;
  • malignancy (except basal cell carcinoma) and/or chemotherapy within 1 year prior to screening; malignancy more than 1 year prior to screening must have been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications;
  • significant unstable medical condition or life threatening disease with anticipated survival of less than 6 months;
  • need for therapies that may obscure the results of treatment and/or of the study
  • Participation in another clinical trial within 30 days of the screening visit;
  • Anticipated inability to attend scheduled study visits;
  • Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedure outlined in this protocol;
  • Patients with a history of prior pharmacogenomic testing;
  • Any change in psychotropic medication (including change in dosage) between screening and baseline;
  • Patients who are known to be pregnant or lactating;
  • Patients with a history of gastric bypass surgery.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.